Compare · AZN vs MAIA
AZN vs MAIA
Side-by-side comparison of AstraZeneca PLC (AZN) and MAIA Biotechnology Inc. (MAIA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and MAIA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $576.71B, about 6974.5x MAIA ($82.7M).
- Over the past year, AZN is down 1.2% and MAIA is down 24.0% - AZN leads by 22.8 points.
- AZN has been more active in the news (21 items in the past 4 weeks vs 13 for MAIA).
- AZN has more recent analyst coverage (25 ratings vs 0 for MAIA).
- Company
- AstraZeneca PLC
- MAIA Biotechnology Inc.
- Price
- $186.00+2.32%
- $1.36-8.72%
- Market cap
- $576.71B
- $82.7M
- 1M return
- +0.65%
- +0.74%
- 1Y return
- -1.21%
- -24.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2026
- 2022
- News (4w)
- 21
- 13
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
- SEC Form 25-NSE filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest MAIA
- MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
- MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
- MAIA Biotechnology Announces Open Market Purchases by CEO and Director
- Chief Executive Officer Vitoc Vlad bought $100,886 worth of shares (72,700 units at $1.39), increasing direct ownership by 8% to 976,121 units (SEC Form 4)
- Director Smith Stan bought $100,200 worth of shares (75,000 units at $1.34) (SEC Form 4)
- Chief Scientific Officer Gryaznov Sergei bought $2,690 worth of shares (2,000 units at $1.34), increasing direct ownership by 4% to 46,511 units (SEC Form 4)
- SEC Form 4 filed by Chief Executive Officer Vitoc Vlad
- SEC Form 4 filed by Chief Scientific Officer Gryaznov Sergei
- SEC Form 4 filed by Head of Finance Himmelreich Jeffrey C
- MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology